Hepatitis C Virus

Results reported in landmark study evaluating Ribavirin in HIV/HCV patients

Published in Hepatitis Weekly, March 8th, 2004

Roche announced that results from the largest study conducted to date evaluating chronic hepatitis C treatment among patients co-infected with HIV and HCV were presented at the 11th annual Conference on Retroviruses and Opportunistic Infections.

The landmark APRICOT (AIDS Pegasys Ribavirin international co-infection trial) study showed 40% of patients treated with Pegasys (peginterferon alfa-2a), the most prescribed chronic hepatitis C treatment in the U.S., and Copegus (ribavirin), achieved a sustained virological response. Sustained virological response refers to a patient's continued undetectable hepatitis C virus levels in the blood 24 weeks after finishing a course...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2004-03-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry